Ipsen S.A.

ENXTPA:IPN Stock Report

Market Cap: €8.9b

Ipsen Past Earnings Performance

Past criteria checks 5/6

Ipsen has been growing earnings at an average annual rate of 23.9%, while the Pharmaceuticals industry saw earnings growing at 14% annually. Revenues have been growing at an average rate of 6.2% per year. Ipsen's return on equity is 16.5%, and it has net margins of 19.3%.

Key information

23.9%

Earnings growth rate

24.0%

EPS growth rate

Pharmaceuticals Industry Growth16.3%
Revenue growth rate6.2%
Return on equity16.5%
Net Margin19.3%
Next Earnings Update13 Feb 2025

Recent past performance updates

Recent updates

What Ipsen S.A.'s (EPA:IPN) P/E Is Not Telling You

Sep 30
What Ipsen S.A.'s (EPA:IPN) P/E Is Not Telling You

These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

Sep 08
These 4 Measures Indicate That Ipsen (EPA:IPN) Is Using Debt Reasonably Well

An Intrinsic Calculation For Ipsen S.A. (EPA:IPN) Suggests It's 42% Undervalued

Jun 16
An Intrinsic Calculation For Ipsen S.A. (EPA:IPN) Suggests It's 42% Undervalued

Ipsen (EPA:IPN) Has Announced A Dividend Of €1.20

May 29
Ipsen (EPA:IPN) Has Announced A Dividend Of €1.20

We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

May 22
We Think Shareholders May Consider Being More Generous With Ipsen S.A.'s (EPA:IPN) CEO Compensation Package

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

May 08
Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

Apr 20
Ipsen (EPA:IPN) Has Affirmed Its Dividend Of €1.20

There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price

Apr 13
There's Reason For Concern Over Ipsen S.A.'s (EPA:IPN) Price

Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Mar 26
Ipsen (EPA:IPN) Seems To Use Debt Quite Sensibly

Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

Dec 30
Investors Still Waiting For A Pull Back In Ipsen S.A. (EPA:IPN)

Revenue & Expenses Breakdown

How Ipsen makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

ENXTPA:IPN Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 243,4356641,157653
31 Mar 243,3716411,146636
31 Dec 233,3066171,135619
30 Jun 233,2824061,105528
31 Mar 233,2195001,072487
31 Dec 223,1565931,039445
30 Sep 223,0536561,007436
30 Jun 222,950719975427
31 Mar 222,849675946425
31 Dec 212,749631916424
30 Sep 212,712626923422
30 Jun 212,676622931420
31 Mar 212,681585951413
31 Dec 202,686548972406
30 Sep 202,697249986404
30 Jun 202,707-501,000403
31 Mar 202,700-531,010396
31 Dec 192,693-551,021389
30 Sep 192,6051761,003363
30 Jun 192,516406986337
31 Mar 192,432397970319
31 Dec 182,348388954302
30 Sep 182,258365931292
30 Jun 182,167343909281
31 Mar 182,090307883274
31 Dec 172,012270858266
30 Sep 171,923243821264
30 Jun 171,834217785262
31 Mar 171,753221752247
31 Dec 161,671226719231
30 Sep 161,623229703214
30 Jun 161,575233687196
31 Mar 161,548211676194
31 Dec 151,520189666193
30 Sep 151,468165651192
30 Jun 151,416140636191
31 Mar 151,374147606189
31 Dec 141,332154577187
30 Sep 141,310155557190
30 Jun 141,287156537193
31 Mar 141,284149543194
31 Dec 131,282142549196

Quality Earnings: IPN has high quality earnings.

Growing Profit Margin: IPN's current net profit margins (19.3%) are higher than last year (12.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: IPN's earnings have grown significantly by 23.9% per year over the past 5 years.

Accelerating Growth: IPN's earnings growth over the past year (63.4%) exceeds its 5-year average (23.9% per year).

Earnings vs Industry: IPN earnings growth over the past year (63.4%) exceeded the Pharmaceuticals industry -19.9%.

Return on Equity

High ROE: IPN's Return on Equity (16.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:46
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ipsen S.A. is covered by 35 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Charles Pitman-KingBarclays
Hae Won NaBerenberg